At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 7,500 enrolled
Drug / intervention
CSL Limited Influenza Vaccine +1 morebiological
Likely dose
CSL Limited Influenza Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years.
In Brief
A Phase 4 clinical trial evaluating CSL Limited Influenza Vaccine and Placebo for Influenza. Completed, enrolled 7,500 participants across 24 sites in 2 countries.
Detailed Summary
This study will assess the Efficacy, Safety and Tolerability profile of CSL's Influenza Vaccine administered intramuscularly against laboratory-confirmed influenza illness in a population defined as being not at risk of severe complications following influenza infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesAustralia, New Zealand
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartMar 2008
Primary CompletionNov 2009
Study CompletionJan 2010
TodayJul 2026
First PostedNov 22, 2007
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.6 years ago
Interventions
CSL Limited Influenza Vaccinebiological
A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
Placebobiological
Placebo